Press release
Investigation announced for Investors who lost money with shares of AN2 Therapeutics, Inc. (NASDAQ: ANTX)
An investigation for investors in AN2 Therapeutics, Inc. (NASDAQ: ANTX) shares over potential securities laws violations.
Investors who purchased shares of AN2 Therapeutics, Inc. (NASDAQ: ANTX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of AN2 Therapeutics, Inc. (NASDAQ: ANTX) concerning whether a series of statements by AN2 Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Menlo Park, CA based AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases.
On February 12, 2024, AN2 Therapeutics, Inc. announced a pause in Phase 3 enrollment in its seamless Phase 2/3 clinical trial (EBO-301) evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review.
Shares of AN2 Therapeutics, Inc. (NASDAQ: ANTX) declined from $21.40 per share on February 06, 2024, to as low as $3.21 per share on February 21, 2024.
Those who purchased shares of AN2 Therapeutics, Inc. (NASDAQ: ANTX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors who lost money with shares of AN2 Therapeutics, Inc. (NASDAQ: ANTX) here
News-ID: 3394468 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for AN2
Non Tuberculous Mycobacterial Infections Market Dynamics Indicate Upward Traject …
The Key Non- Tuberculous Mycobacterial Infections Companies in the market include - Insmed, AN2 Therapeutics, Mannkind Corporation, Spero Therapeutics, Savara Pharmaceuticals, Mallinckrodt Inc., Paratek Pharmaceuticals Inc., Revimmune, and others .
The Non- Tuberculous Mycobacterial Infections market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non- Tuberculous Mycobacterial Infections pipeline products will significantly revolutionize the Non- Tuberculous Mycobacterial Infections market…
Nontuberculous Mycobacterial Infection Market Outlook 2034 - Clinical Trials, Ma …
Nontuberculous Mycobacterial Infections Market Size in the US was approximately USD 360 million in 2023 and is projected to increase during the forecast period (2024-2034).
Nontuberculous Mycobacterial Market Summary
The Nontuberculous Mycobacterial (NTM) infections market is expected to grow steadily from 2024 to 2034, driven by improved diagnostics, new therapies, and greater disease awareness. Aging populations, who are more susceptible to NTM infections, contribute to rising diagnosed cases. Current treatments rely on…
Nontuberculous Mycobacterial Infections Market: Epidemiology, Therapies, Compani …
Nontuberculous Mycobacterial Infections therapies, such as ARIKAYCE (amikacin liposome inhalation suspension), Epetraborole, MNKD-101 (Clofazimine Inhalation Suspension), SPR720 (Fobrepodacin), and others, are expected to boost the Nontuberculous Mycobacterial Infections Market in the upcoming years.
DelveInsight has launched a new report on "Nontuberculous Mycobacterial Infections - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Nontuberculous Mycobacterial Infections, historical and forecasted epidemiology as well as the Nontuberculous Mycobacterial Infections…
Nontuberculous Mycobacterial Infections Treatment Market Size in the 7MM is expe …
DelveInsight's "Nontuberculous Mycobacterial Infections Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of NTM Infections, historical and forecasted epidemiology, as well as the NTM Infections market trends in the United States.
Discover Key Insights into the Nontuberculous Mycobacterial Market with DelveInsight's In-Depth Report @ Nontuberculous Mycobacterial Market Size- https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Nontuberculous Mycobacterial Market Report
• According to DelveInsight's epidemiology model, the total Nontuberculous…
MAC Lung Disease Market Statistics Expected to Experience Major Growth by 2034, …
DelveInsight's "MAC Lung Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the MAC Lung Disease, historical and forecasted epidemiology as well as the MAC Lung Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of MAC Lung Disease, offering comprehensive insights into the MAC Lung Disease revenue trends,…
Non- Tuberculous Mycobacterial Infections Market on Track for Major Expansion by …
The Key Non- Tuberculous Mycobacterial Infections Companies in the market include - Insmed, AN2 Therapeutics, Mannkind Corporation, Spero Therapeutics, Savara Pharmaceuticals, Mallinckrodt Inc., Paratek Pharmaceuticals Inc., Revimmune, and others.
The Non- Tuberculous Mycobacterial Infections market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non- Tuberculous Mycobacterial Infections pipeline products will significantly revolutionize the Non- Tuberculous Mycobacterial Infections market dynamics.
DelveInsight's…
